Israel Englander’s MoonLake Immunotherapeutics MLTX Stock Holding History

Israel Englander’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,000	Closed	-$71.7K	–	6291
2025 Q3	$71.7K	Buy	+10,000	New	+$521K	﹤0.01%	5771
2025 Q1	–	Sell	-10,000	Closed	-$542K	–	6199
2024 Q4	$542K	Buy	+10,000	New	+$511K	﹤0.01%	4692
2024 Q2	–	Sell	-10,200	Closed	-$512K	–	6290
2024 Q1	$512K	Sell	10,200 -17,000	-63%	-$922K	﹤0.01%	4796
2023 Q4	$1.64M	Buy	+27,200	New	+$1.4M	﹤0.01%	3768

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Israel Englander's MLTX Position: Q2 2026 in Review

Israel Englander increased its MoonLake Immunotherapeutics (MLTX) stake by 10% in Q2 2026, buying an estimated $1.09M and bringing the position to 636,187 shares worth $12.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2071.

Israel Englander first reported a position in MLTX in Q4 2020 and has held it in 19 quarters since. The position peaked at $13.5M in Q1 2025. 171 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Israel Englander held 636,187 shares of MoonLake Immunotherapeutics worth $12.4M as of Q2 2026.
Israel Englander bought 60,095 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $1.09M.
MoonLake Immunotherapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2071 holding.
Israel Englander first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 19 quarters since.
Israel Englander's MoonLake Immunotherapeutics position peaked at $13.5M in Q1 2025.
171 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.